Alexander Uihlein
Endocrinology, Diabetes & Metabolism · Greenbrae, CANPI 1801043880
Payments from drug & device makers
Across 184 payments — averaging $535.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Radius Health, Inc.$73K
- Gilead$23K
- Amgen$1K
- Tandem Diabetes Care, Inc.$300
- Lilly USA, LLC$270
- Novo Nordisk$208
- plus $266 from 9 others
What the payments were for
- Speaking & faculty fees$3008%
- Travel & lodging$79821%
- Food & beverage$2,51167%
- Education$1554%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Radius Health, Inc. | 81 | $73,345 |
| Gilead | 14 | $22,938 |
| Amgen | 53 | $1,183 |
| Tandem Diabetes Care, Inc. | 1 | $300 |
| Lilly USA, LLC | 14 | $270 |
| Novo Nordisk | 8 | $208 |
| Companion Medical, Inc. | 4 | $70 |
| AstraZeneca | 2 | $35 |
| Ascendis Pharma Endocrinology Inc | 1 | $27 |
| Abbott | 1 | $26 |
| Boehringer Ingelheim | 1 | $23 |
| Ultragenyx Pharmaceutical Inc. | 1 | $23 |
| Insulet Corporation | 1 | $21 |
| IBSA Pharma Inc. | 1 | $21 |
| Zealand Pharma US, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- t-slim insulin pump$300
- Tymlos$100
How this compares
$98,510 in reported general payments places this provider in the 85th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ForteoTeriparatide | 190 | $261,561 |
| OzempicSemaglutide | 81 | $61,370 |
| TymlosAbaloparatide | 13 | $58,032 |
| MounjaroTirzepatide | 22 | $24,913 |
| JardianceEmpagliflozin | 45 | $24,817 |
| Victoza 2-PakLiraglutide | 19 | $12,228 |
| Levothyroxine Sodium | 460 | $9,235 |
| OmnitropeSomatropin | 14 | $8,995 |
| Testosterone | 112 | $8,712 |
| Liothyronine Sodium | 58 | $3,457 |
| Methimazole | 184 | $3,272 |
| Hydrocortisone | 45 | $2,924 |
| Insulin Glargine-Yfgn | 38 | $2,729 |
| Eplerenone | 18 | $2,658 |
| SynthroidLevothyroxine Sodium | 13 | $2,448 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCForteo, Mounjaro | $270 | $286,474212 claims |
| Novo NordiskOzempic | $208 | $61,37081 claims |
| Radius Health, Inc.Tymlos | $73,345 | $58,03213 claims |
| Boehringer IngelheimJardiance | $23 | $24,81745 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in Greenbrae
- Linda GaudianiGreenbrae$2.9M
- Steven HarrisGreenbrae$564K
- Jerrold OlefskySan Diego$26.5M
- Mark ChristiansenWalnut Creek$22.9M
- Timothy BaileyEscondido$22.3M
- Stanley HsiaLos Angeles$19.8M
- Juan FriasSan Diego$14.1M
- Paul NorwoodFresno$6.2M
- Athena Philis-Tsimikasla Jolla$6M
- David AhnNewport Beach$5.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.